Alethio Therapeutics

€80.5M Series A

Announced: Nov 6, 2026
Sector: Biotechnology
Investors: 5

Summary

Alethio Therapeutics completed an oversubscribed €80.46 million Series A financing to advance its blood cancer therapies. Alethio Therapeutics is a developer of therapies for myeloproliferative neoplasms.

Investors

Sofinnova Partners, RA Capital, Oxford Science Enterprises, Cancer Research Horizons, University of Oxford